Drugs / UTAA06
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05722171 | Dec 2022 → Dec 2023 | acute myeloid leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06372236 | Dec 2023 → May 2025 | — | Peking University | Completed | No outcome recorded |
| Phase 1 | NCT05731219 | Sep 2022 → Sep 2023 | acute myeloid leukemia | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UTAA06 | “Main research purpose： Evaluate the safety and tolerance of UTAA06 injection in the treatment of patients with relapsed/refractory acute myeloid leukemia.” NCT05731219 ↗ |
| Modality | Cell therapy | “B7-H3 target, CAR gene modified gdT cell injection” NCT05731219 ↗ |